CBLI - Cleveland Bio pops 4% after SEC declared effectiveness of registration statement

Cleveland BioLabs (CBLI) perks up 4% after announcing that its registration statement Form S-4 filed in connection with its previous merger with Cytocom was declared effective by the SEC on June 10, 2021. The registration statement includes a definitive proxy statement and a prospectus. Subsequent to the closing of the merger, the new combined company will be named "Cytocom Inc.", and its common stock is expected to trade on Nasdaq under the symbol "CYTO".The merger is expected to close in Q3 2021.Biopharma Cytocom creates next-generation immune therapies that deliver immune homeostasis.

For further details see:

Cleveland Bio pops 4% after SEC declared effectiveness of registration statement